Prescrire Int. 1999 Jun;8(41):70-1.
(1) Bambuterol is a long-acting metabolic precursor of terbutaline, marketed as an oral preparation. It is approved for long-term treatment of asthma and other reversible obstructive airways diseases. (2) The clinical file on bambuterol is sparse. There is no evidence that bambuterol has any advantages in terms of efficacy relative to oral terbutaline or inhaled salmeterol. (3) The claimed (minimal) advances relative to oral terbutaline, in terms of adverse effects (low level of evidence) and the advantage of once-daily dosing, are in no way decisive.
(1) 班布特罗是特布他林的长效代谢前体，作为口服制剂上市。它被批准用于哮喘和其他可逆性阻塞性气道疾病的长期治疗。(2) 关于班布特罗的临床资料稀少。没有证据表明班布特罗在疗效方面相对于口服特布他林或吸入沙美特罗有任何优势。(3) 相对于口服特布他林所宣称的（极小的）进展，在不良反应方面（证据级别低）以及一日一次给药的优势，都绝不是决定性的。
